26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
02 October 2019IDWeek 2019IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America…read more >>
26 September 2019Institut Pasteur : Table ronde sur La résistance aux agents antimicrobiensÀ l’occasion de la visite de Jim O’Neill, ancien secrétaire d’État britannique, le professeur Stewart Cole, directeur général de l’Institut…read more >>
25 September 2019Phage Futures EuropeTranslating phage-based applications into clinically and commercially viable therapeuticsread more >>
10 September 2019REVIVE webinar: Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease researchIn this webinar, Peter Warn will review the experimental design and conduct of advanced or complex animal models for antimicrobial…read more >>
06 September 2019CeBIL Annual Symposium 2019: Legal Innovation to Support the Development of Antimicrobial DrugsThis symposium will explore the complex interactions between law and antimicrobial research and development. Advancing our understanding of this ecosystem…read more >>
03 September 2019ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial ResistanceAntimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority…read more >>
20 August 2019REVIVE webinar: Models for antimicrobial R&D: Computational modelling for population PK and PKPDIn this webinar, Lena Friberg and Elisabet Nielsen (Department of Pharmaceutical Biosciences, Uppsala University, Sweden), will discuss: - Population PK…read more >>
16 July 2019OBN BioTuesday: What’s New in Antimicrobial Resistance – is there light at the end of the tunnel?The development of resistance to antimicrobials threatens to reverse the changes in public health that have occurred over the last…read more >>
09 July 2019REVIVE webinar: Infection models for antimicrobial R&D: Intracellular modelsIn this webinar, Françoise van Bambeke, Research Director Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Catholic University of Louvain…read more >>
